Article Per Year (5 Year)
p-Index From 2020 - 2025
0.61
P-Index
This Author published in this journals
All Journal Pharmaciana: Jurnal Kefarmasian Indonesian Journal of Pharmaceutical Science and Technology Jurnal Ilmiah Farmako Bahari
Meilia Suherman, Meilia
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Chemistry Computer Science & IT Health Professions Medicine & Pharmacology

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Performance Evaluation of Molecularly Imprinted Polymer using Propanol as Porogen for Atenolol Recognition in Human Serum Suherman, Meilia; Susanti, Ike; Rahayu, Driyanti; Pratiwi, Rimadani; Nur Hasanah, Aliya
Indonesian Journal of Pharmaceutical Science and Technology Vol 6, No 1 (2019 In Press)
Publisher : Indonesian Journal of Pharmaceutical Science and Technology

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (532.992 KB) | DOI: 10.15416/ijpst.v6i1.18671

Abstract

Atenolol is a cardiovascular drug that has a narrow therapeutic index with long-term use and it’s often used as doping. Atenolol has a small concentration in human boby and it’s in  biological matrix (serum) so in the testing need a selective extraction so  the analyte can be pra-concentration and removed from matrix. Two molecularly imprinted polymers (MIPs) on propanol as porogen  have been made with two different methods i.e. bulk polymerization and precipitation polymerization. The polymer was made using atenolol as a template, methacrylic acid as a functional monomer, and ethylene glycol dimethacrylate as a crosslinker. Prformance evaluations showed that polymers from bulk polymerization provide better performance than polymers from precipitation polymerization when tested against standard solution. However, this sorbent has low  recovery percentage after applied into serum sample and could not be used as alternative for atenolol extraction in human serum.Key words: Molecularly imprinted polymer, Atenolol, Solid Phase Extraction, Preparation  method, propanol.
IN SILICO STUDY: SECONDARY METABOLITES FROM JAMBOLAN (Syzygium Cumini L.) AS POTENTIAL BREAST CANCER TREATMENTS Suherman, Meilia; Junaedi, Effan Cahyati; Prasetiawati, Riska; Purnamasari, Ade Rena
Jurnal Ilmiah Farmako Bahari Vol 15, No 2 (2024): Jurnal Ilmiah Farmako Bahari
Publisher : Faculty of Mathematic and Natural Science, Garut University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52434/jifb.v15i2.3254

Abstract

Breast cancer ranks second in world cancer incidence rates in 2020, contributing to 2,261,419 new cases, or 11.7% of all new cancer cases globally. The search for cancer drugs that work selectively continues to be encouraged to obtain safe and effective therapy, particularly those derived from medicinal plants. Jambolan is a plant that can thrive in both subtropical and tropical climates, including Indonesia. Jambolan (Syzygium cumini L.) has 89% antioxidant activity and 69% cytotoxic activity against T47D cells. Pharmacophore modelling and molecular docking were used to study the binding of 117 active jambolan drugs to alpha and beta estrogen receptors. Rutin was found to be potentially selective for ER-Beta receptors, with a fit score of 53.13. Molecular docking to ER-Beta revealed that rutin has breast cancer activity with a free bond energy value of -10.5 kcal/mol and better conformation and affinity than native ligands (genistein). It also binds to essential amino acids as an anticancer breast at ARG 346 and GLU 305. Lipinski's rule of five prediction results and in silico ADMET prediction from rutin yielded results that met the candidate drug's parameters. Rutin is a potential therapeutic option for treating breast cancer by targeting the ER-Beta receptor.
IN SILICO STUDY: SECONDARY METABOLITES FROM JAMBOLAN (Syzygium Cumini L.) AS POTENTIAL BREAST CANCER TREATMENTS Suherman, Meilia; Junaedi, Effan Cahyati; Prasetiawati, Riska; Purnamasari, Ade Rena
Jurnal Ilmiah Farmako Bahari Vol 15 No 2 (2024): Jurnal Ilmiah Farmako Bahari
Publisher : Faculty of Mathematic and Natural Science, Garut University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52434/jifb.v15i2.3254

Abstract

Breast cancer ranks second in world cancer incidence rates in 2020, contributing to 2,261,419 new cases, or 11.7% of all new cancer cases globally. The search for cancer drugs that work selectively continues to be encouraged to obtain safe and effective therapy, particularly those derived from medicinal plants. Jambolan is a plant that can thrive in both subtropical and tropical climates, including Indonesia. Jambolan (Syzygium cumini L.) has 89% antioxidant activity and 69% cytotoxic activity against T47D cells. Pharmacophore modelling and molecular docking were used to study the binding of 117 active jambolan drugs to alpha and beta estrogen receptors. Rutin was found to be potentially selective for ER-Beta receptors, with a fit score of 53.13. Molecular docking to ER-Beta revealed that rutin has breast cancer activity with a free bond energy value of -10.5 kcal/mol and better conformation and affinity than native ligands (genistein). It also binds to essential amino acids as an anticancer breast at ARG 346 and GLU 305. Lipinski's rule of five prediction results and in silico ADMET prediction from rutin yielded results that met the candidate drug's parameters. Rutin is a potential therapeutic option for treating breast cancer by targeting the ER-Beta receptor.
In silico study: secondary metabolites from malay apple (Syzygium malaccense (L.) Merr. & L.M. Perry) as potential breast cancer treatments Prasetiawati, Riska; Fauzan, Nawadhir; Suherman, Meilia
Pharmaciana Vol. 13 No. 3 (2023): Pharmaciana
Publisher : Universitas Ahmad Dahlan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.12928/pharmaciana.v13i3.26537

Abstract

Breast cancer has the highest prevalence of all cancers. Breast cancer has overtaken lung cancer as the leading cause of global cancer incidence in 2020, accounting for 2,261,419 new cases, or 11.7% of all new cancer cases worldwide. Among the efforts that can be done are efforts to find breast cancer medications that are safe and selective for the treatment and prevention of cancer, particularly those derived from medicinal plants. The Malay apple (Syzygium malaccense (L.) Merr. and L.M. Perry) is one plant that has been extensively examined and proved to have an antiproliferative effect. The pharmacophore modelling, molecular docking, and molecular dynamic approach was conducted on 155 active compounds of Malay apple to alpha and beta estrogen receptors. According on the results of ER-lamda docking, numerous substances have binding free energy values less than 4-OHT yet are not bound to important amino acids, as the result, it is not continued to the next test. On other side, with a fit score of 45.81, rutin was potentially selective for ER-beta receptors, molecular docking to ER-beta obtained that rutin was predicted to have breast cancer activity with a free binding energy value of -10.6 kcal /mol with better conformation and affinity compared to native ligand (genistein), and bound to essential amino acids as anticancer breast at ARG 346, GLU 305,  and molecular dynamics simulations show that the compound has good stability when binding to the receptor. In silico toxicity prediction from rutin showed outcomes that match the requirements for the candidate drug. However, because it does not match the ADME prediction and Lipinsky's rule of five, rutin must be optimalization to improve its pharmacokinetic and pharmacological profile before it can be further explored as a therapeutic option for the treatment of breast cancer that targets the ER- receptor.
Co-Authors Aliya Nur Hasanah Driyanti Rahayu Fauzan, Nawadhir Ike Susanti Junaedi, Effan Cahyati Purnamasari, Ade Rena Rimadani Pratiwi Riska Prasetiawati, Riska